Jentadueto 01
Jentadueto Tablet, Film Coated
Product Images NDC 0597-0148
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Jentadueto (NDC 0597-0148). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Jentadueto 02
Jentadueto 03
Jentadueto 04
This appears to be a table showing the number of patients at risk and the percentage of patients experiencing an event for a placebo group and a group receiving a drug called Linagliptin. However, without more information about the study or what the event is, it is impossible to provide further context or meaning.*
Jentadueto 05
This is a report of two medications, Linagliptin and Glimepiride, and their dosages. There is also a chart showing the number of patients taking each medication at different times. The data suggests that there were 3023 patients on Linagliptin at the start of the trial, and the number decreased over time. Conversely, the number of patients taking Glimepiride increased over time, starting at 3010 patients, and peaking at 2833 patients around the 15th time point. Overall, the purpose of this report is unclear without further context.*
Jentadueto 06
Jentadueto 07
Each tablet contains 2.5 mg inagliptin and 850 mg of metformin hydrochloride. Dosage instructions are listed in the package insert. The medication should be stored at 20-25°C, with excursions permitted to 15-30°C [see USP Controlled Room Temperature]. The medication should be protected from high humidity and kept out of reach of children. The product is distributed by Boehringer Ingelheim Pharmaceuticals, Inc. and is manufactured in Mexico. This medication is a prescription drug containing linagliptin and metformin hydrochloride and is used to treat diabetes. Dispense the accompanying medication guide to each patient. Lot and expiration information are also provided.*
Jentadueto 08
Each tablet of Jentadueto contains 2.5 mg of linagliptin and 1000 mg of metformin hydrochloride. The package insert should be consulted for dosage and prescribing information. The tablets should be stored between 20°C-25°C (68°F-77°F) with excursions permitted to 15°C-30°C (59°F-86°F), and protected from high humidity. The product should be kept out of reach of children. Distributed by Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT 06877 USA and made in Mexico. The trademark and product are licensed by Boehringer Ingelheim International GmbH. A medication guide must be dispensed to each patient.*
Jentadueto 09
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
